Cancer biotherapy & radiopharmaceuticals
Cancer Biotherapy and Radiopharmaceuticals covers immunotherapy, targeted biological agents and radiolabelled drugs for cancer imaging and treatment, read by nuclear medicine and biotherapy researchers.
Overview
Cancer Biotherapy & Radiopharmaceuticals has been published since 1996 and, according to the NLM catalogue, is issued from 2026 by SAGE Publications in Thousand Oaks, California, following its long run with Mary Ann Liebert; Crossref lists SAGE Publications as the publisher. As its title indicates, its two subjects are cancer biotherapy, meaning biological agents used to treat cancer, and radiopharmaceuticals, meaning radiolabelled compounds used to image and treat it. The NLM record lists it as a United States serial that is indexed in MEDLINE; it is not listed in DOAJ.
Pages like this
not linked directly; found by shared links- IdeaCAIX theranostics: 89Zr-girentuximab PET and 177Lu/225Ac-girentuximab therapy
Shares Radio-antibody & radio-ADC, Radioligand therapy (beta emitters).
- TechnologyAuger-electron therapy
Shares Radio-antibody & radio-ADC, Radioligand therapy (beta emitters).
- CompanyAbdera Therapeutics
Shares Radio-antibody & radio-ADC, Radioligand therapy (beta emitters).
- RoadmapRadiopharmaceutical roadmap: iodine → lutetium → actinium
Shares Radio-antibody & radio-ADC, Radioligand therapy (beta emitters).